Advisor Net Financial, Inc Genmab A/S Transaction History

Advisor Net Financial, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 12, 2024	BUY	$26.43 - $32.77 $845 - $1,048	32 New	32 $0
Q3 2022 Oct 04, 2022	SELL	$31.52 - $373.61 $2,962 - $35,119	-94 Reduced 78.33%	26 $1,000
Q2 2022 Jul 07, 2022	SELL	$26.83 - $38.57 $2,414 - $3,471	-90 Reduced 42.86%	120 $4,000
Q1 2022 Apr 14, 2022	SELL	$30.95 - $39.68 $1,733 - $2,222	-56 Reduced 21.05%	210 $8,000
Q4 2021 Jan 19, 2022	BUY	$35.87 - $47.12 $1,793 - $2,356	50 Added 23.15%	266 $11,000
Q3 2021 Oct 15, 2021	BUY	$41.55 - $48.72 $8,974 - $10,523	216 New	216 $9,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Advisor Net Financial, Inc, based on Form 13F filings with the SEC.

Stay updated on Advisor Net Financial, Inc with notifications on news.